Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,433 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,452 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03729297 | Cabozantinib in Advanced Salivary Gland Cancer Patients(Cabo ASAP) | terminated | Phase 2 | 25 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT00084682 | Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2021 | clinicaltrials |
| NCT04554680 | Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy | unknown | Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT01620242 | A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes(ORL03) | completed | Phase 2 | 31 | UNICANCEROTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT01716195 | Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer | completed | Phase 2 | 18 | University of California, DavisOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04769076 | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 25, 2021 | clinicaltrials |
| NCT00904345 | Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) | terminated | Phase 2 | 23 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT00006051 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer | completed | Phase 2 | — | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03638622 | Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.(UH3-India) | completed | Phase 1 / Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01270321 | Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer | completed | Phase 2 | 42 | Emory UniversityOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03072160 | Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2021 | clinicaltrials |
| NCT03668366 | S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 133 | Fudan UniversityOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT02636231 | Endostar for Locally Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04440917 | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma(IMplus) | unknown | Phase 2 | 32 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03558035 | New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma | unknown | Phase 2 | 96 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03915132 | Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 47 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT01414426 | Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | completed | Phase 2 | 20 | University of ChicagoOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT03887442 | Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy(EXTAX) | terminated | Phase 2 | 17 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 0 | Jan 7, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT00514046 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2020 | clinicaltrials |
| NCT02138214 | Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer | completed | Phase 2 | 117 | University of Wisconsin, MadisonOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02423863 | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®(Poly-ICLC) | completed | Phase 2 | 26 | Oncovir, Inc.INDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00210470 | A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer | completed | Phase 2 | 27 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 0 | Dec 11, 2020 | clinicaltrials |
| NCT01689194 | Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer | completed | Phase 2 | 53 | Seoul National University HospitalOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT01412229 | Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03349034 | Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps | completed | Phase 2 | 24 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT04627961 | A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 33 | National University Hospital, SingaporeOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04612894 | Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT01386632 | Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma | completed | Phase 2 | 50 | Sanford HealthOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | withdrawn | Phase 2 | 0 | Alain AlgaziOTHER | 0 | Oct 26, 2020 | clinicaltrials |
| NCT00005088 | Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 2 | — | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 22, 2020 | clinicaltrials |
| NCT00006360 | Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer | completed | Phase 1 / Phase 2 | — | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 22, 2020 | clinicaltrials |
| NCT02976051 | DAHANCA 33: Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic HNSCC | unknown | Phase 2 | 60 | Danish Head and Neck Cancer GroupNETWORK | 1 | Oct 20, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04574817 | Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) | unknown | Phase 2 | 66 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03129412 | Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions | unknown | Phase 2 | 64 | Zhejiang Cancer HospitalOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04553510 | Treatment of Bevacizumab Followed by Steroid in RN | unknown | Phase 2 | 86 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | terminated | Phase 1 / Phase 2 | 19 | Daiichi SankyoINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04547088 | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04548271 | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT00736944 | Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer | completed | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04058145 | AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04220749 | Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | withdrawn | Phase 2 | 0 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2020 | clinicaltrials |
| NCT04534855 | A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 0 | Sep 1, 2020 | clinicaltrials |
| NCT04525066 | Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma | completed | Phase 2 | 39 | Ayhman Al AfifOTHER | 0 | Aug 25, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Mar 12, 2021source: clinicaltrials